Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS

Kaplan-Meier estimates for the probabilities of (a) OS, and (b) EFS by treatment group in 215 patients treated with BuCy2 (- - - -) and Bu-Flu (—) (the numbers within parenthesis indicate number of events and cohort size).

Kaplan-Meier Estimates for the probabilities of (a) NRRS, and (b) RFS, by treatment group in 215 patients treated with BuCy2 (- - - -) and Bu-Flu (—) (the numbers within parenthesis indicate number of events and cohort size).

Survival of patients transplanted in CR1, “early disease” with BuCy2 (- - - -) and Bu-Flu (—); (a) OS, and (b) EFS in all CR1 patients. In graphs (c) OS, and (d) EFS is depicted for patients up to and including 40 years of age (the numbers within parenthesis indicate number of events and cohort size).

Posterior distribution under the lognormal regression model for (a) OS, and (b) EFS of the corrected Bu-Flu versus BuCy2 treatment effect. In these plots, p denotes the probability of a beneficial effect of Bu-Flu versus BuCy2, and is represented by the area of the shaded region in the respective figure.

Posterior distributions under the lognormal regression model for (a) NRRS, and (b) RFS of the corrected Bu-Flu versus BuCy2 treatment effect within the 215 Bu-treated patients. In the plot, p denotes the probability of beneficial effect of Bu-Flu versus BuCy2, and is represented by the area of the shaded region in the respective figure.